The clearest takeaway was that the conversation has shifted. The sector is no longer asking whether genomics belongs in Australia’s digital health systems, it is asking how to get there at scale.

InGeNA CEO Dr Erin Evans chaired a packed panel, From Data to DNA: AI, Genetics and the Future of Precision Health, alongside Tiffany Boughtwood, Professor Paul Lacaze and Sarah Powell. Discussion centred on moving AI and genetic testing from research into real-world care, with a focus on scaling support, strengthening primary care capability and building the workforce and interoperability infrastructure precision health requires.

Professor Daniel MacArthur’s keynote posed a question that stayed with the room: what does industry need Australia to invest in? From InGeNA’s perspective, the answer is commitment and clarity around enabling infrastructure  MSAC reform, digital interoperability and implementation pathways that connect testing, clinical workflows and patient access.

Beyond the sessions, we reconnected with Dr Natalie Thorne and the Genomical team, Dr Jill Freyne from AWS, Dr Danya Vears and Aine Heaney from Medcast, the myDNA team, and inaugural InGeNA members David Bunker and David Driscoll, a reminder of how connected and active this community is.

Thank you to the Digital Health Festival team for another outstanding event.